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Abstract Clinical evidence indicates that bone status is
affected in patients with type 2 diabetes mellitus (T2DM).
Regardless of normal or even high bone mineral density,
T2DM patients have increased risk of fractures. One class
of antidiabetic drugs, thiazolidinediones (TZDs), causes
bone loss and further increases facture risk, placing TZDs
in the category of drugs causing secondary osteoporosis.
Risk factors for development of TZD-induced secondary
osteoporosis are gender (women), age (elderly), and
duration of treatment. TZDs exert their antidiabetic effects
by activating peroxisome proliferator-activated receptor-γ
(PPAR-γ) nuclear receptor, which controls glucose and
fatty acid metabolism. In bone, PPAR-γ controls differen-
tiation of cells of mesenchymal and hematopoietic lineages.
PPAR-γ activation with TZDs leads to unbalanced bone
remodeling: bone resorption increases and bone formation
decreases. Laboratory research evidence points toward a
possible separation of unwanted effects of PPAR-γ on bone
from its beneficial antidiabetic effects by using selective
PPAR-γ modulators. This review also discusses potential
pharmacologic means to protect bone from detrimental
effects of clinically used TZDs (pioglitazone and rosiglita-
zone) by using combinational therapy with approved
antiosteoporotic drugs, or by using lower doses of TZDs
in combination with other antidiabetic therapy. We also
suggest a possible orthopedic complication, not yet sup-
ported by clinical studies, of delayed fracture healing in
T2DM patients on TZD therapy.
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Introduction
Diabetes affects 180 million individuals worldwide with
prevalence in all ages including very young children. The
most common form is insulin-independent, or type 2
diabetes mellitus (T2DM). T2DM is characterized by
insulin and glucose intolerance, and it is associated with
development of hyperglycemia and hyperinsulinemia.
Available therapies include insulin, insulin secretagogues
(sulfonylureas), and glucose-lowering drugs (thiazolidine-
diones [TZDs], biguanide, and incretins) [1]. Out of these,
only TZDs have insulin-sensitizing properties and are the
most efficient for management of poorly controlled diabetes
[1]. TZDs target peroxisome proliferator-activated receptor-
γ (PPAR-γ) protein, a key regulator of energy metabolism
in fat tissue. In response to the nutrients availability, such as
glucose and fatty acids, PPAR-γ controls energy storage
and its dissipation by regulating lipogenesis and lipolysis
[2]. These activities of PPAR-γ include production of
proteins involved in carbohydrate and fatty acids metabo-
lism, as well as production of fat-specific cytokines,
adipokines, which regulate insulin sensitivity in peripheral
tissues. In bone, PPARγ controls bone cell development
and the cytokine milieu of the bone marrow environment
[3]. It regulates lineage commitment toward osteoblasts and
adipocytes from common mesenchymal stem cells (MSCs),
and bone resorbing osteoclasts from the pool of hemato-
poietic progenitors. In addition, PPAR-γ controls produc-
tion of a variety of cytokines, which support hematopoiesis,
including receptor activator of nuclear factor-κB ligand
(RANKL), which supports osteoclastogenesis.
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The status of bone mineral density (BMD) and the risk of
bone fractures in T2DM have been assessed in a number of
studies. In general, individuals with T2DM have normal or
increased BMD compared with nondiabetic patients;
however, they have a higher incidence of bone fractures
[4￿]. Systematic analysis of 16 different well-controlled
studies conducted in the United States and in Europe
showed that T2DM was associated with a twofold increase
in risk of hip fractures in men (relative risk [RR], 2.8) and
women (RR, 2.1) [5]. Studies performed on a Japanese
population indicated that T2DM patients, both women
(odds ratio [OR], 1.83; P<0.01) and men (OR, 4.73;
P<0.001), have increased rate of vertebral fractures [6].
Increased fracture risk is additionally elevated by diabetic
complications including macrovascular complications,
diabetic eye and kidney diseases, and neuropathy [7],
which may lead to increased risk of trauma due to more
frequent incidence of falls (RR, 1.64) [8]. In addition,
factors such as duration of diabetic disease, aging, prior
fracture, and corticosteroid use contribute to the greater
fracture risk [9].
A lack of association between BMD and fracture risk
suggests that diabetic bone has altered biomechanical
quality. Human histomorphometric studies indicate that
bone turnover in older T2DM patients is compromised,
which may result in higher BMD but decreased bone
quality [10]. Recent animal studies showed that high levels
of insulin lead to high bone mass by decreasing both
osteoclast number and bone resorption, and osteoblast
number and bone formation [11]. Moreover, highly reactive
glucose metabolites (advance glycation end products
[AGEs]), of which circulating levels are increased in
diabetes, are implicated in forming additional cross-links
between collagen fibers in bone [12]. This process affects
bone biomechanical properties by increasing its stiffness
and fragility [13]. In support of this, recent studies showed
a positive association between levels of circulating AGE
pentosidine and increased incidence of fractures in diabetic
patients [12, 14￿].
TZDs for Treatment of Type 2 Diabetes: Beneficial
and Adverse Effects
Two US Food and Drug Administration (FDA)–approved
TZDs, rosiglitazone (Avandia; GlaxoSmithKline, Research
Triangle Park, NC) and pioglitazone (Actos; Takeda
Pharmaceuticals, Deerfield, IL), have been in clinical use
since 1999. These drugs are used as glucose-lowering
agents with a beneficial effect on insulin sensitivity. In
addition to improving glycemic control in T2DM patients,
they improve lipid metabolism with pioglitazone having a
more favorable impact on serum lipids, lipoproteins, and
apolipoproteins than rosiglitazone [15].
A number of studies showed superior efficacy of TZDs
over other available antidiabetic therapies in the control of
diabetic hyperglycemia [16]. However, their prolonged use
is associated with several adverse effects. Strong clinical
evidence points to the connection between rosiglitazone use
and a significant increase in risk of myocardial infarction
and death from cardiovascular causes [17]. This association
resulted in a recent review of rosiglitazone safety by the
FDA [18]. Interestingly, pioglitazone use is associated with
a significantly lower risk of death and lower number of
myocardial infarction and stroke incidence [19], indicating
that cardiovascular effects of TZDs are not a drug class
effect, but rather specifically associated with the TZD type.
Both TZDs exhibit drug class properties of fluid retention
and weight gain [20].
TZD’s Effect on Bone: Clinical Research Evidence
There is accumulating evidence that both rosiglitazone and
pioglitazone cause bone loss and increase fracture risk in
humans, specifically in women [4￿]. Observational studies
using data from the Health, Aging, and Body Composition
cohort reported that older postmenopausal TZD users
experience bone loss at the rate of -0.61% annually
compared with non-TZD users [21]. In Japanese patients
with T2DM, treatment for 1 year with pioglitazone
decreased serum osteocalcin, femoral and radial BMD, but
not BMD in lumbar vertebra [22]. Bone loss was also
observed with a short treatment with TZDs. A randomized,
placebo-controlled study of the effect of pioglitazone on
bone in polycystic ovary syndrome patients in Denmark
demonstrated that 16 weeks of treatment resulted in a
significant decline in BMD of the lumbar spine (−1.1%)
and femoral neck (−1.4%) [23]. Similarly, a randomized
controlled trial of rosiglitazone effects on bone of post-
menopausal nondiabetic women in New Zealand showed
that 14 weeks of rosiglitazone administration resulted in a
decrease in hip BMD by -1.9% compared with the BMD at
the beginning of treatment [24]. Changes in BMD were
accompanied by a decrease in serum markers of bone
formation, such as alkaline phosphatase and aminoterminal
propeptide of type I collagen (P1NP). Bone resorption
markers lacked change, leading to the conclusion that short-
term therapy with rosiglitazone exerts detrimental skeletal
effects by inhibiting bone formation [24]. In contrast,
16 weeks of treatment with rosiglitazone of T2DM women
with a prior diagnosis of cardiovascular disease resulted in
significantly increased levels of the circulating bone
resorption marker C-terminal collagen crosslinked peptide
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same studies showed that rosiglitazone did not affect
markers of bone turnover in men [25]. The contrasting
results of studies by Grey et al. [24] and Gruntmanis et al.
[25] suggest that bone response to TZDs may be deter-
mined by hormonal and metabolic status.
The causal connection between TZD therapy and
increased fracture risk was determined in a number of
studies, the majority of which were retrospective. The
analysis of these studies allows for defining of risk factors
to increased fractures in TZD users such as gender, age,
pre-existing conditions, and duration of treatment. The first
demonstration of increased fracture risk was noticed during
an analysis of results from ADOPT (A Diabetes Outcome
Progression Trial), which was designed to compare an
efficacy of different antidiabetic therapy on maintenance of
normal glucose levels in prediabetic individuals [16]. Post-
trial data from the 1,840 women and 2,511 men randomly
assigned in ADOPT to rosiglitazone, metformin, or
glyburide for a median of 4.0 years were examined with
respect to time to first fracture, rates of occurrence, and
sites of fractures [16, 26￿]. Fracture rate in men did not
differ between treatment groups and did not demonstrate
significant difference in an overall risk. The cumulative
incidence of fractures in women was 15.1% (11.2–19.1)
with rosiglitazone, 7.3% (4.4–10.1) with metformin, and
7.7% (3.7–11.7) with glyburide, representing hazard ratios
of 1.81 and 2.13 for rosiglitazone compared with metformin
and glyburide, respectively. Fractures were seen predomi-
nantly in the lower and upper limbs, and vertebral fractures
were not assessed in this study. Increased fracture rate in
women correlated with increased levels in serum of bone
resorption marker (CTX) but not bone formation marker
(P1NP) [27]. There was no correlation between rosiglita-
zone use and estrogen status since both pre- and postmeno-
pausal women demonstrated increase in fractures [16, 26￿].
These observations were subsequently corroborated by a
number of other studies. A meta-analyses of data from 10
different randomized controlled trials involving 13,715
participants and two observational studies involving
31,679 participants confirmed that long-term TZD use
doubles the risk of fractures exclusively in women but not
in men with T2DM [28￿]. Recently, the cross-sectional
study based on use of medical and pharmacy claims for
TZD prescriptions and involving the southeastern region
of the United States showed that TZD use, regardless of
type, doubled the incidence of distal upper and lower limb
fracture, and the proportion was significantly higher in
women and increased 2% for every year increase in age
[29]. Similarly, retrospective studies involving 19,070
individuals of both genders in southeast Michigan showed
that women more than 65 years of age appeared to be at
greatest risk for fractures [30].
In contrast, retrospective studies on 84,339 diabetic
patients in British Columbia (Canada) concluded that both
women and men receiving TZDs have increased fracture
risk. The risk further increased with duration of treatment,
and pioglitazone was more strongly associated with
fractures than rosiglitazone, especially in men [31]. Obser-
vational studies based on the UK General Practice Research
Database (GPRD), which included a large population of
older individuals, showed that TZD therapy and its duration
are associated with significant increase in nonvertebral
fractures independent of patient sex and age. The adjusted
OR of fracture occurrence for hip/femur was 4.54, for
humerus was 2.12, and for wrist/forearm was 2.90 [32].
Studies conducted on a cohort of Medicare beneficiaries
with diabetes over 65 years of age and older showed that
compared with sulfonylureas and metformin monothera-
pies, TZD monotherapy is associated with increased risk of
peripheral fractures regardless of sex and type of TZD [33].
Another self-controlled case-series study on the GPRD
population suggested that prior fracture(s) increases the risk
of the next fracture occurrence. These studies compared
rates of fractures within the person with prior fracture
during TZD exposed and unexposed periods and showed
that exposure to TZD, either rosiglitazone or pioglitazone,
increased fracture rate by 43% similarly in men and women
and the duration of exposure increased this risk even further
[34]. Fractures occurred in a range of sites including hip,
spine, arm, foot, wrist, and hand.
Taken together, results of available studies indicate the
following: 1) TZD effect on bone is a drug class effect; 2)
women and elderly are at increased risk of bone loss and
increased risk of fractures; however, some studies point to
the equal risk in both genders; 3) the risk is increased in
individuals who have a history of prior TZD-unrelated
fractures; and 4) duration of treatment correlates positively
with increased fracture risk.
On a positive note, TZD’s negative effect on bone can be
beneficial in treatment of conditions of increased bone
formation. Treatment with rosiglitazone of an acromegalic
patient with T2DM significantly decreased serum levels of
growth hormone and insulin-like growth factor-1 (IGF-1),
and improved acromegalic features [35]. This clinical
observation points to the possibility of using TZDs in
patients with pituitary tumors associated with increased
growth hormone production. Another case report suggests
t h a tT Z D sm a yb eu s e dt os l o wd o w np r o g r e s so f
fibrodysplasia ossificans progressiva (FOP). FOP is a
genetic disease characterized by heterotopic bone formation
due to upregulation of bone morphogenetic protein (BMP)
signaling in response to inflammatory input [36]. It has
been reported that rosiglitazone not only prevented new
flares of heterotopic bone formation, but also improved
general mobility of the FOP patient [36]. TZD’s negative
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TZD’s Effect on Bone: Laboratory Research Evidence
TZDs bind to and activate the PPAR-γ transcription factor,
which is a key regulator of bone cell development and their
activity in the adult skeleton [3]. In animal models, TZDs
induce bone loss by affecting the bone remodeling process;
TZDs suppress new bone formation by osteoblasts and
increase bone resorption by osteoclasts. Age and sex steroid
status determine which mechanism contributes predomi-
nantly to the observed bone loss. An administration of
rosiglitazone to mice for a period of 8 weeks resulted in
significant decreases in BMD, bone volume, and changes in
bone microarchitecture [37, 38]. Observed bone loss was
associated with changes in the structure and function of
bone marrow, which included decreased number of osteo-
blasts, increased number of adipocytes, and increased
support for osteoclastogenesis. The degree of bone loss in
response to rosiglitazone correlated with the animal age and
the level of PPAR-γ expression in bone [38]. In younger
animals with less PPAR-γ, trabecular bone loss in the
proximal tibia was associated with a decreased number of
osteoblasts and a reduced bone formation rate. In older
animals with higher levels of PPAR-γ, bone loss correlated
with an increased number of osteoclasts and increased bone
resorption, whereas the quantity of osteoblasts and the bone
formation rate remained unchanged [38]. Similarly, estro-
gen deficiency influences TZD-induced bone loss in murine
models. Studies of rosiglitazone effects in estrogen-
deficient rats and mice showed that bone loss occurred
mainly due to increased bone resorption [39, 40],
pointing to the functional cross-talk between PPAR-γ
and estrogen receptor. Such cross-talk has been recently
described in osteoblasts as a form of competition between
PPAR-γ and estrogen receptor for a common coactivator,
steroid receptor coactivator-2 (Src-2) [41]. In conclusion,
animal studies suggest that aging and estrogen deficiency
confound TZD-induced bone loss and determine its
mechanism.
Two mechanisms may contribute to increased bone
resorption: an increased production by mesenchymal cells
of osteoclastogenesis supporting cytokine RANKL and
activation of PPAR-γ in cells of hematopoietic lineage
[38, 42]. As showed recently, PPAR-γ promotes osteoclast
recruitment and differentiation from hematopoietic progen-
itors by controlling an expression of c-fos protein, an
important determinant of osteoclast lineage commitment
and development [42, 43]. Mice deficient in PPAR-γ
expression in cells of hematopoietic lineage develop
osteopetrosis and are less sensitive to the TZD-induced
bone loss than control mice [42].
TZD’s negative effects on bone formation raise a
concern regarding their effects on bone healing. Studies
from our laboratory have shown that TZDs interfere with
new bone formation at the bone healing site. In a distraction
osteogenesis model of intramembraneous bone formation,
we have shown that rosiglitazone significantly decreases
endosteal bone formation. This effect is associated with a
decreased number of bone-forming osteoblasts, decreased
new vessel formation, and accumulation of large quantities
of fat at the healing site (Lecka-Czernik, Unpublished data).
The negative effect of TZDs on fracture healing should be
addressed in clinical studies, and if confirmed, a discontin-
uation of TZD therapy during the period of fracture healing
should be considered.
Studies on molecular and cellular mechanisms activated
by TZDs suggest that in marrow cells of mesenchymal
lineage TZDs suppress bone anabolic signaling by decreas-
ing activity of Wnt, transforming growth factor-β (TGF-β)/
BMP, and IGF-1 pathways, while inducing production of
RANKL, a cytokine supporting osteoclast development
[38, 44￿]. The effects on activities of TGF-β/BMP and IGF-
1 pathways may explain in part the beneficial effects of
TZDs on treatment of FOP and acromegaly, as mentioned
above [35]. The decrease in activity of osteoblast-specific
signaling pathways precedes the negative effects of TZDs
on the expression of genes essential for osteoblast devel-
opment, such as Runx2, Dlx5, and Osterix. Moreover,
TZDs affect the expression of genes involved in the
maintenance of MSC-like phenotype, so-called “stemness”
genes such as LIF and c-kit, while inducing the expression
of adipocyte-specific genes [45￿]. As a result, MSCs lose
their potential to differentiate toward osteoblasts. Instead,
they acquire an adipocyte phenotype. These features
resemble changes that occur during MSC aging, and which
result in a decreased number of osteoblasts and bone
formation, and accumulation of fat in bone marrow [46, 47].
Moreover, the number of osteoclasts and production of
RANKL increases with aging, and results in increased bone
resorption [48]. Because TZD-induced changes in bone
marrow structure/function are strikingly similar to changes
that occur during aging, some speculate that TZDs accelerate
the aging of bone [38, 46].
Selective PPAR-γ Modulators: Ligand-Dependent
Separation of Proadipocytic and Antiosteoblastic
Activities of PPAR-γ
The PPARγ ligand-binding domain contains a large
binding pocket capable of encompassing a variety of
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points that can result in various PPAR-γ conformations and
differential recruitment of coactivators, which determine
specificity of this nuclear receptor [2]. Although TZDs
possess a beneficial antidiabetic profile, their adverse
effects prompt pharmaceutical efforts to develop selective
PPAR-γ modulators that will retain high potency to treat
diabetic disease with minimal adverse effects [49].
The molecular studies provide evidence for distinct
regulatory pathways that regulate proadipocytic and antios-
teoblastic activities of PPAR-γ. These studies demonstrated
that PPAR-γ proadipocytic activity is transcriptional in nature
and involves binding to PPAR response elements (PPRE) in
generegulatoryregions,whereasitsantiosteoblasticactivityis
PPRE-independent [44￿]. PPAR-γ anti-inflammatory and
antiatherogenic activities are also regulated in a PPRE-
independent manner [50].
With respect to bone, it has been demonstrated that
PPAR-γ proadipocytic and antiosteoblastic activities can be
separated by using ligands of different chemical structures
[51]. In an in vitro model of marrow mesenchymal cell
differentiation under control of PPAR-γ, ligands consisting
of several structurally related oxidized derivatives of
linoleic acid were able to activate all three combinations
of PPAR-γ activity: proadipocytic, antiosteoblastic, or
both. In addition, we have shown that the TZD netoglita-
zone, which has antihyperglycemic properties comparable
with rosiglitazone, does not suppress osteoblastogenesis.
Mice receiving netoglitazone at the dose that decreased
glucose levels similarly to rosiglitazone did not lose bone
[52].
Can We Prevent Secondary Osteoporosis in TZD Users?
Clinical evidence indicating an increased risk of bone loss
and fractures in TZD users requires more research address-
ing an improvement to bone safety. Advances in develop-
ment of new pharmacologic means to treat diabetes are
broadening the arsenal of drugs that target different but
complementary mechanisms of glucose metabolism. Com-
bination therapies that focus on different mechanisms
promise better pharmacologic outcome with a possibility
to reduce doses of each particular drug. A combination of
TZDs with metformin reduces the dose of TZDs by half
and was shown to control hyperglycemia, hemoglobin A1c
(HbA1c) levels, and prevent progression to diabetes of
prediabetic individuals [53]. Both rosiglitazone and piogli-
tazone are available in such combinations known as
Avandamet (GlaxoSmithKline) and ACTOplus met (Takeda
Pharmaceuticals), respectively. Another possibility is a
combination of TZDs with incretin-based therapy. Although
TZDs have a negative effect on bone, incretins seem to
have a positive effect by stimulating anabolic activities
of osteoblasts and suppressing catabolic activities of
osteoclasts [54]. From the diabetic benefit point of view,
i th a sb e e nd e m o n s t r a t e dt h a tT Z D si nc o m b i n a t i o nw i t h
glucagon-like peptide-1 analogues, or with dipeptidyl
peptidase-4 serine protease inhibitors, allows for better
control of hyperglycemia and HbA1c levels [55]. However,
the safety for bone of such combined therapies has not
been investigated as yet.
Whereas combined therapy with other antidiabetic drugs
may minimize a negative effect on bone, the therapy in
which TZDs are administered in combination with anti-
osteoporotic drugs (eg, bisphosphonates) may protect bone.
Administration of alendronate with pioglitazone to aging
mice completely protected bone from its loss compared
with the group of animals receiving pioglitazone alone
(Lecka-Czernik, Unpublished data). In view of recent
unfavorable reviews of rosiglitazone safety, it is possible
that a competitor pioglitazone will remain on the market as
the only available TZD. Taking into account its continued
use because of its beneficial effect for control of diabetes,
more research has to be done to improve bone safety during
pioglitazone therapy.
Conclusions
The available evidence indicates that antidiabetic TZD
therapy is associated with bone loss and increased fracture
risk. The mechanism of TZD-induced bone loss includes
unbalanced bone remodeling processes resulting from
decreased bone formation and increased bone resorption.
Human and animal studies suggest that aging and estrogen
deficiency confound TZD-induced bone loss and determine
its mechanism. Improvement of bone safety of TZD-based
therapy may be achieved by using combination therapy
with other antidiabetic therapies, or preventing bone loss by
using available antiosteoporotic drugs, or development of a
new class of selective TZDs, which may have sparing or
even beneficial effects on skeleton. A new provocative
question is the effect of TZDs on fracture healing in
diabetic patients. This question requires clinical studies to
assess a risk of orthopedic complications in TZD users, and
may caution against continuation of TZD therapy during a
period of fracture healing.
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